LANSOPRAZOL

Treatment of duodenal ulcer:

The recommended dose is 30 mg once daily for 2 weeks. In patients whose healed is not complete after this period, treatment will be continued at the same dosage, for an additional two weeks.

Treatment of gastric ulcer:

The recommended dose is 30 mg once daily for 4 weeks. The ulcer usually heals within 4 weeks, but in patients whose healing is not complete after this period, treatment may be continued at the same dosage, for an additional 4 weeks.

Reflux oesophagitis:

The recommended dose is 30 mg once daily for 4 weeks. In patients whose recovery is not complete after this period, the treatment may be continued at the same dose for an additional 4 weeks. Prophylaxis of reflux oesophagitis: 15 mg once daily.

The dose may be increased up to 30 mg daily as necessary.

Eradication of Helicobacter pylori:

The choice of appropriate combination therapy should be made according to official local recommendations regarding bacterial resistance, duration of treatment, (usually 7 days but sometimes up to 14 days), and appropriate use of antibacterial agents.

The recommended dose is 30 mg of Lansoprazole twice daily for 7 days in combination with one of the following: clarithromycin 250-500 mg twice daily + 1 g of amoxicillin twice daily clarithromycin 250 mg twice daily + metronidazole 400-500 mg twice daily Eradication rates of H.

pylori up to 90%, are achieved when clarithromycin is combined with Lansoprazole gasto-resistant capsules and amoxicillin or metronidazole. Six months after successful eradication treatment, the risk of re-infection is low and relapse is therefore unlikely.

The use of a dose comprising lansoprazole 30 mg twice daily, amoxicillin 1 g twice daily and metronidazole 400-500 mg twice daily has also been studied. Using this combination, lower eradication rates were observed than for dosages involving clarithromycin.

They can be adapted for patients who cannot take clarithromycin as part of an eradication therapy, when local resistance rates to metronidazole are low. Treatment of NSAID induced duodenal ulcers and benign gastric ulcer in patients requiring continued NSAID treatment: 30 mg once daily for four weeks.

Tabulated list of adverse reactions. Frequencies are defined as common (≥ 1/100 to < 1/10); uncommon (≥ 1/1,000 to <1/100); rare (≥1/10,000 to <1/1,000); very rare (<1/10,000), not known (cannot be estimated from the available data).

For all post-marketing adverse reactions, it is not possible to apply any frequency of adverse reactions, so they are reported with an "indeterminate" frequency. Within each frequency grouping, adverse reactions are presented in order of decreasing seriousness.

Common Uncommon Rare Very rare Frequency not known Hematological and lymphatic system disorders Thrombo- cytopenia, Eosinophilia, Leucopenia Anaemia Agranulocytosis, pancytopenia Immune system disorders Anaphylactic shock Metabolism and nutrition disorders Hyponatremia* Hypomagnesaemia*, hypocalcaemia*#, hypokalaemia*# Psychiatric Disorders Depression Insomnia, Hallucination, confusion Visual hallucinations Nervous system Disorders Headache, dizziness Impatience, dizziness, Paresthesia, drowsiness, tremor Eye disorders Visual disturbances.

4) Reporting of suspected adverse reactions Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.

Malignant gastric tumor As with other anti-ulcer treatments, the possibility of malignant gastric tumour should be rule out when treating a gastric ulcer with lansoprazole as lansoprazole can mask the symptoms and delay the diagnosis.

5). Hypomagnesaemia Severe hypomagnesaemia has been reported rarely in patients treated with proton pump inhibitors (PPIs) such as lansoprazole for at least three months, and in most cases for one year. Hypomagnesaemia can manifest itself by severe clinical sign such as fatigue, tetany, delirious flushing, convulsions, dizziness and ventricular arrhythmia, but it can begin insidiously and go unnoticed.

8). In most patients, hypomagnesaemia (and hypomagnesaemia associated with hypocalcaemia and/or hypokalaemia) improved after magnesium supplementation and PPI discontinuation. , diuretics), blood magnesium testing should be considered by health care professionals prior to initiation of PPI therapy and then regularly during treatment.

Influence on the absorption of vitamin B12 Daily treatment with any acid-suppressing medications over a prolonged period of time (several years) may lead to malabsorption of cyanocobalamin (vitamin B12) caused by hypo- or achlorhydria.

This should be taken into account in patients with reduced reserves or with risk factors for decreased absorption of vitaminB12 during long-term treatment or if clinical symptoms are observed. 2). Gastrointestinal bacterial infections Lansoprazole, like other PPI treatments, may be associated with an increased risk of infection with Clostridium difficile.

A decreased in gastric acidity due to lansoprazole may increase levels of bacteria normally found in the gastrointestinal tract. Treatment with lansoprazole may lead to a slight increased risk of gastrointestinal infections especially due to Salmonella and Campylobacter.

Eradication of Helicobacter pylori In patients with peptic ulcers, the possibility of infection with H. pylori as an etiological factor should be considered. pylori, then the conditions for the use of these antibiotics should also be followed.

1.